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1. Introduction 
Extensively purified commercial preparations [l] 
of lima bean protease inhibitor (LBI) can be further 
separated into at least four biologically active variants 
by ion exchange chromatography [2, 31. These 
variants have similar but not identical amino acid 
compositions and tryptic peptide maps [2-41. 
Previous studies [3-8] on the structure, biological 
activity and mode of action of LB1 have been per- 
formed using either the mixture of variants or indi- 
vidual variant preparations. In the present study we 
provide the first comprehensive comparison of the in- 
hibitory activities of four variants of LBI. 
For the sake of clarity it should be recalled that 
LB1 can inhibit both trypsin and chymotrypsin 
through the formation of equimolar complexes with 
these enzymes and that the binding sites for trypsin 
and chymotrypsin on LB1 are distinct and indepen- 
dent [4-61. We have previously identified a Lys-Ser 
peptide bond in the anti-trypsin site of LB1 [4, 7, 81; 
incubation of LB1 with catalytic amounts of trypsin 
at acid pH results in an equilibrium mixture of native 
and trypsin-modified inhibitor (LBI;) in which this 
Lys-Ser peptide bond has been hydrolysed [7]. 
LBI; combines with trypsin slower than does LB1 and 
therefore it appears less active than LB1 in an assay 
system which does not involve preincubation between 
enzyme and inhibitor. Removal of the newly formed 
carboxyterminal lysine residue with carboxypeptidase 
B results in complete loss of trypsin inhibitory 
actirity. Incubation of LBI; with near molar amounts 
of trypsin at neutral pH results in eventual complex 
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formation and upon dissociation of the complex by 
acidification, native LB1 with the Lys-Ser bond 
intact can be recovered from the reaction mixture 
[7, 81. In similar fashion treatment of LB1 with 
catalytic amounts of chymotrypsin at acid pH yields 
a mixture of native and chymotrypsin-modified LB1 
(LBIL) in which a specific Leu-Ser peptide bond 
has been hydrolyzed [4, 51. In the LB1 variant on 
which previous work was carried out [ 51 the complex 
formation between LBI: and chymotrypsin was too 
slow to be observed under routine assay conditions. 
In the present paper four variants of LB1 prepared 
from a commercial preparation of LB1 by the method 
of Jones et al. [2] are compared with respect to i) the 
trypsin and chymotrypsin inhibitory activity of the 
native inhibitor, ii) the extent of modification of the 
inhibitor by incubation at acid pH with catalytic 
amounts of trypsin or chymotrypsin and iii) the 
kinetics of complex formation between LBI’, and 
trypsin and LBI’, and chymotrypsin. The results in- 
dicate that the four LB1 variants are essentially identi- 
cal with respect to their trypsin inhibitory activity 
but show marked differences in their affinity for 
chymotrypsin in either the native or the chymotryp- 
sin-modified form. 
2. Materials and methods 
2.1. Materials 
Lima bean protease inhibitor (LB1 lDA), bovine 
trypsin (TRL 2DA), bovine chymotrypsin (CD1 8GA) 
and carboxypeptidase B (COBDFP 1CA) were 
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obtained from Worthington (Freehold, N.J.). The in- 10.4 and after addition of 25 rul carboxypeptidase B 
hibitor was further purified on Sephadex G-75 and solution (2.5 mg/ml) incubated overnight at 37” prior 
separated into its four variants on DEAE-cellulose as to assay. This treatment is known to completely in- 
described by Jones et al. [2]. They were named with activate LBI; by removal of the new carboxyterminal 
roman numerals I through IV in order of their elution lysine while leaving native LB1 unaffected [7, 81; any 
from the column. Three times crystallized porcine activity remaining in the reaction mixture after this 
trypsin (4-36-564 Batch UK6) was obtained from treatment would be due to native LBI. Analogous 
Miles Laboratories, Inc. (Kanakakee, Ill.). Benzoyltyrosine treatment of the chymotryptic reaction mixture was 
not necessary since the complex formation between 
LBI’, and chymotrypsin is too slow to interfere with 
the assay system (see Results and discussion section). 
ethyl ester and p-toluenesulfonylarginine methyl ester 
were purchased from Mann Research Laboratories 
(New York, N.Y.). All other chemicals were reagent 
grade or better. 
2.2. Inhibitor assays 3. Results and discussion 
The inhibitory activities of LBI, LBI; and LBI’, 
were determined with the spectrophotometric assay 
previously described by Rhodes et al. [9, lo]. 
Benzoyltyrosine ethyl ester and p-toluenesulfonyl- 
arginine methyl ester were used as the synthetic sub- 
strates for chymotrypsin and trypsin, respectively. 
The substrate-indicator solution was either added 
immediately after mixing of enzyme and inhibitor or, 
where needed, after previous incubation of the 
enzyme-inhibitor mixture at room temp. for the 
appropriate time. The amount of enzyme and in- 
hibitor used was calculated from the weight of the 
dry lyophilized powder. 
3.1. Inhibitory activities of the four LBI variants 
Fig. 1 shows the trypsin inhibitory activities of 
native LB1 and of the reaction mixture of native LB1 
and LBI; after treatment with carboxypeptidase B to 
remove the “slow” inhibitory activity due to LBI’+. It 
be seen that these four variants of LB1 have e CiUl 
40 
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2.3. Modification of LBI by trypsin and chymotrypsin 
and determination of the extent of modification 
LB1 was dissolved in 0.018 M transaconitate buffer, 
pH 3.1 containing 0.04 M CaCl, to a final protein 
concentration of approx. 10 mg/ml. For the produc- 
tion of LBI; the inhibitor solution was incubated 
with 2 mole percent porcine trypsin for 76 hr at 25’. 
A control was treated in identical fashion except that 
the trypsin was omitted. The chymotrypsin modifica- 
tion of LB1 was carried out under the same conditions 
except that 1 mole percent of bovine chymotrypsin 
was added to the solution and the reaction mixture 
was incubated for 14 hr at 25’. The conditions for 
trypsin and chymotrypsin modification were chosen 
on the basis of previous experience to yield equilib- 
rium mixtures between native and enzyme-modified 
inhibitor. To determine the extent of modification of 
the trypsin-modified inhibitor 50 fi samples (450 I.cg) 
of both control and reaction mixture were adjusted 
to pH 8.0 by the addition of 40 d 0.1 M borate, pH 
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Fig. 1. Trypsin inhibitory activity of four variants of native 
and trypsin-modified LBI. Assays were carried out as 
described in the text. Increasing amounts of inhibitor were 
added to 30 pg of trypsin and the mixture was preincubated 
in the assay medium for 15 min before the addition of the 
substrate-inhibitor solution. In order to differentiate between 
LB1 and LBI’t all samples were previously treated with 
carboxypeptidase B as described in the text..(-) 
Mixture of LB1 and LBI’t; ( -1 native LBI. 
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Fig. 2. Chymotrypsin inhibitory activity of four variants of 
native and chymotrypsin-modified LBI. Increasing amounts 
of inhibitor were added to 45 pg of chymotrypsin and the 
assays were carried out as described in the text without pre- 
incubation. (o-o--o ) Mixture of LBI’, and LBI; (-) 
native LBI. 
similar if not identical trypsin inhibitory capacities. 
From these results the percentage of LBI; in the 
reaction mixtures and therefore the extent of modifi- 
cation of LB1 by catalytic amounts of trypsin at acid 
pH can be calculated. The values for LB1 variants I 
through IV are 93%, 90%, 93% and 82%, respectively. 
These values are considerably higher than those 
previously reported by us [5, 81. It has been shown 
[7, 1 l] that this is due to the fact that in previous 
studies we did not reach the true equilibrium between 
LB1 and LBI;. Fig. 2 shows that, even though by extra- 
polation it can be seen that the equivalence point may be 
virtually identical for the four variants, there are vast 
differences in their actual chymotrypsin inhibitory 
activity. While vartant IV seems to be a strong in- 
hibitor of chymotrypsin at near molar amounts, 
variant I achieves only approx. 60% inhibition even 
when present in a large molar excess. LB1 variants II 
and III appear intermediate in their chymotrypsin in- 
hibitory activity. This difference in chymotrypsin in- 
hibitory activity of the variants probably indicates 
that the Kdiss for the LBI-chymotrypsin complex is 
largest for LB1 I and decreases progressively through 
variants II, III and IV. On the other hand, the extent 
of modification of the LB1 variants by incubation 
with catalytic amounts of bovine chymotrypsin at 
acid pH appears to be identical. In every case the 
equilibrium mixture contains approx. 90% LBI’, 
and 10% native LBI. 
3.2. Kinetics of complex formation between LBI; 
and trypsin and LBI’, and chymotrypsin 
It is generally accepted [ 121 that the inhibitory 
activity as measured here is actually a measure of the 
extent of complex formation between enzyme and 
inhibitor. Fig. 3 shows that while complex formation 
between native LB1 and trypsin is complete in less 
than 1 min, the complex formation of LBI; variants 
I through IV takes about S- 15 min. It appears there- 
fore that the variants are almost identical with 
respect to i) trypsin inhibitory activity, ii) extent of 
modification by trypsin at acid pH as well as iii) the 
kinetics of complex formation between LBI; and 
trypsin. 
Fig. 4 on the other hand illustrates the differences 
in affinity for chymotrypsin between LBI’c variants. 
Incubation Time In Minutes 
Fig. 3. Time course study of the trypsin inhibitory capacity 
of LB1 and LBl’t variants I through IV. Assays were carried 
out as described in the text, but enzyme-inhibitor mixtures 
were incubated in the assay medium for varying amounts of 
time prior to addition of the substrate. (- 130 rgof 
trypsin (control); (W I 30 pg of trypsin and 9.1 pg of 
the reaction mixture of LB1 and LBI’t; (- )30PcgOf 
trypsin and 9.1 pg of native LBI. 
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variants. In experiments now in progress we are trying 
to relate these differences in chymotrypsin inhibitory 
activity to structural differences between the variants. 
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Fig. 4. Time course study of the chymotrypsin inhibitory 
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amounts of time prior to addition of the substrate. (u) 
45 pg of chymotrypsin (control); (w ) 45 rug of chymo- 
trypsin and 27 pg of the reaction mixture of LB1 and LBI’,; 
(~4) 45 r.rg of chymotrypsin and 27 pg of native LBI. 
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